Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech’s plans are rooted in an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.
You may also be interested in...
High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
US FDA Appears To Quickly Renege On Next-Gen COVID Vaccine Guidance With Updated Booster Announcement
After issuing guidance and making public statements saying the first updated COVID-19 vaccines would require clinical trial data, agency picks new vaccine composition that will make obtaining such data highly unlikely before a planned fall booster campaign.
EU Sustainable Chemicals Program Could Impact 60% Of Fragrance Ingredients – Givaudan
Certain rose, jasmine, cedarwood, freesia, lavender, apple, orange and musk fragrance ingredients could be eliminated purely on the basis of hazard if EU sustainable chemical principles are implemented as discussed across sectors and regulatory programs, according to Givaudan’s Greg Adamson, senior VP, global regulatory affairs and product safety for fragrance and beauty.